Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company`s preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Website: aptevotherapeutics.com



Growth: Good revenue growth rate 50.0%, there is acceleration compared to average historical growth rates 38.2%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -236.4%. On average the margin is decreasing steadily. Gross margin is low, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$1.76 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 120.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 1 151.9% higher than minimum and 83.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -7.9x by EV / Sales multiple

Key Financials (Download financials)

Ticker: APVO
Share price, USD:  (0.0%)1.62
year average price 5.0535  


year start price 1.6200 2025-10-20

min close price 0.5499 2025-12-29

max close price 9.8300 2026-01-20

current price 1.6200 2026-10-19
Common stocks: 2 559 527

Dividend Yield:  0.0%
EV / Sales: -2.3x
Margin (EBITDA LTM / Revenue): -236.4%
Fundamental value created in LTM:
Market Cap ($m): 4
Net Debt ($m): -29
EV (Enterprise Value): -25
Price to Book: 0.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-26accessnewswire.com

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

2025-11-10accessnewswire.com

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

2025-08-13accessnewswire.com

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

2025-06-20benzinga.com

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

2025-03-20accessnewswire.com

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

2025-02-15accessnewswire.com

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

2025-02-14accessnewswire.com

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

2025-01-10zacks.com

Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?

2024-12-12accesswire.com

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

2024-12-04accesswire.com

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-11 2024-11-07 2024-08-08 2024-05-08 2023-09-30 2023-08-10 2023-05-11 2022-11-10 2022-08-11
acceptedDate 2025-11-06 16:18:03 2025-08-11 08:12:36 2025-02-14 08:52:59 2024-11-07 08:30:22 2024-08-08 08:30:27 2024-05-08 08:30:44 2024-03-05 08:30:32 2023-09-29 20:00:00 2023-08-10 08:30:35 2023-05-11 08:31:26 2023-03-30 08:01:58 2022-11-10 08:30:56 2022-08-11 08:31:34 2022-03-24 08:30:47 2021-03-31 08:00:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 3M 0 0 12M 4M
costOfRevenue 0 0 352 000 0 91 000 106 000 0 123 000 150 000 0 0 0 0 0 18M
grossProfit 0 0 -352 000 0 -91 000 -106 000 0 -123 000 -150 000 0 3M 0 0 12M -14M
grossProfitRatio 0 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 4M 3M 14M 3M 4M 4M 17M 4M 5M 4M 18M 4M 4M 19M 18M
generalAndAdministrativeExpenses 4M 3M 10M 2M 2M 3M 12M 3M 3M 4M 14M 3M 4M 15M 14M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 4M 3M 10M 2M 2M 3M 12M 3M 3M 4M 14M 3M 4M 15M 14M
otherExpenses 0 0 -352 000 0 141 000 149 000 0 227 000 230 000 -67 000 0 0 0 0 -18M
operatingExpenses 8M 6M 24M 5M 6M 7M 29M 7M 8M 8M 32M 8M 8M 34M 14M
costAndExpenses 8M 6M 25M 5M 6M 7M 29M 7M 8M 8M 32M 8M 8M 34M 32M
interestIncome 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
interestExpense 0 0 0 0 0 0 0 0 0 -10M 0 25 000 0 0 0
depreciationAndAmortization 49 000 49 000 352 000 84 000 91 000 106 000 567 000 123 000 150 000 -10M 901 000 222 000 276 000 1M 1M
ebitda -8M -6M -24M -5M -6M -7M -28M -6M -8M -17M -28M -8M 28M -20M -26M
ebitdaratio 0 0 0 0 0 0 0 0 0 0
operatingIncome -8M -6M -25M -5M -6M -7M -29M -7M -8M -8M -29M -8M -8M -21M -27M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 61 000 22 000 472 000 112 000 141 000 149 000 10M 227 000 230 000 10M 36M -25 000 35M -8M -3M
incomeBeforeTax -8M -6M -24M -5M -6M -7M -19M -6M -8M 2M 7M -8M 28M -29M -31M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 62 724 0 0 0 -10M 0 -140 000 0 0 0
netIncome -8M -6M -24M -5M -6M -7M -17M -6M -8M 11M 8M -8M 28M -28M -18M
netIncomeRatio 0 0 0 0 0 0 0 0 0 0
eps -40.134 -151.287 -31 458 -0.48 -1.67 -9.95 -834 044 -22.16 -1.23 1.62 922 390 -1.51 5.58 -4M -6M
epsdiluted -40.134 -151.287 -0.48 -1.67 -9.95 -22.16 -1.23 1.62 -1.51 5.58
weightedAverageShsOut 224 946 41 008 767.047 11M 4M 686 735 20.875 285 886 6M 7M 8.702 5M 5M 7.999 5.786
weightedAverageShsOutDil 224 946 41 008 767.047 11M 4M 686 735 20.875 285 886 6M 7M 8.707 5M 5M 7.999 5.786
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-03-05 2023-03-30 2022-03-24 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 0 0 0 0 0
ebit -24M -29M -29M -21M -27M
nonOperatingIncomeExcludingInterest -472 000 0 0 0 0
netIncomeFromContinuingOperations -24M -19M 7M -29M -31M
netIncomeFromDiscontinuedOperations 0 1M 1M 951 000 13M
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -24M -17M 8M -28M -31M
epsDiluted -31 458 -834 044 921 915 -4M -6M

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-11 2024-11-07 2024-08-08 2024-05-08 2023-09-30 2023-08-10 2023-05-11 2022-11-10 2022-08-11
acceptedDate 2025-11-06 16:18:03 2025-08-11 08:12:36 2025-02-14 08:52:59 2024-11-07 08:30:22 2024-08-08 08:30:27 2024-05-08 08:30:44 2024-03-05 08:30:32 2023-09-29 20:00:00 2023-08-10 08:30:35 2023-05-11 08:31:26 2023-03-30 08:01:58 2022-11-10 08:30:56 2022-08-11 08:31:34 2022-03-24 08:30:47 2021-03-31 08:00:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 21M 9M 9M 8M 8M 10M 17M 19M 21M 25M 23M 22M 29M 45M 40M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 21M 9M 9M 8M 8M 10M 17M 19M 21M 25M 23M 22M 29M 45M 40M
netReceivables 0 0 0 0 0 0 0 0 0 0 3M 0 0 4M 2M
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 2M 2M 256 000 2M 2M 2M 689 000 649 000 764 000 2M 744 000 658 000 2M 2M 3M
totalCurrentAssets 23M 11M 11M 10M 10M 12M 19M 21M 23M 28M 27M 25M 31M 53M 47M
propertyPlantEquipmentNet 4M 5M 5M 5M 5M 6M 6M 6M 6M 6M 7M 7M 7M 4M 6M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 0 0 -1 0 0 0 -6M 0 0 0 0 68 000 746 000
totalNonCurrentAssets 4M 5M 5M 5M 5M 6M 6M 6M 6M 6M 7M 7M 7M 4M 6M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
totalAssets 27M 16M 16M 15M 15M 18M 25M 27M 29M 35M 34M 32M 39M 57M 54M
accountPayables 2M 3M 3M 4M 4M 4M 0 4M 5M 0 0 3M 3M 0 0
shortTermDebt 0 0 0 0 0 0 0 0 0 0 2M 2M 2M 12M 5M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 3M 2M 3M 2M 2M 3M 7M 3M 2M 6M 7M 3M 2M 23M 10M
totalCurrentLiabilities 6M 5M 6M 6M 5M 6M 7M 7M 7M 6M 9M 8M 7M 35M 15M
longTermDebt 4M 4M 0 5M 5M 5M 0 6M 6M 6M 1M 8M 9M 4M 20M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 14 000 14 000 14 000 0 0 0 0 0 3M 0 16M 0
totalNonCurrentLiabilities 4M 4M 5M 5M 5M 5M 5M 6M 6M 6M 8M 8M 9M 21M 22M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 4M 4M 5M 0 5M 5M 5M 6M 6M 6M 6M 6M 6M 1M 2M
totalLiabilities 10M 9M 11M 11M 10M 12M 13M 12M 13M 12M 16M 16M 16M 55M 37M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 110 000 99 000 84 000 82 000 69 000 66 000 61 000 56 000 49 000 49 000 48 000 47 000 47 000 47 000 46 000
retainedEarnings -269M -260M -248M -241M -236M -230M -223M -218M -211M -203M -206M -201M -194M -214M -186M
accumulatedOtherComprehensiveIncomeLoss -0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
othertotalStockholdersEquity 286M 267M 246M 241M 236M 232M 227M 226M 217M 217M
totalStockholdersEquity 17M 7M 5M 4M 4M 6M 12M 15M 16M 23M 18M 16M 23M 1M 17M
totalEquity 17M 7M 5M 4M 4M 6M 12M 15M 16M 23M 18M 16M 23M 1M 17M
totalLiabilitiesAndStockholdersEquity 27M 16M 15M 15M 18M 27M 29M 35M 32M 39M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 27M 16M 16M 15M 15M 18M 25M 27M 29M 35M 34M 32M 39M 57M 54M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 4M 4M 5M 5M 5M 5M 5M 6M 6M 6M 10M 10M 11M 17M 27M
netDebt -17M -5M -4M -3M -3M -5M -12M -14M -15M -19M -13M -12M -19M -28M -13M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-03-05 2023-03-30 2022-03-24 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 3M 4M 2M
prepaids 2M 1M 2M 2M 2M
totalPayables 3M 0 0 0 0
otherPayables 0 0 0 0 0
accruedExpenses 0 0 0 0 0
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 5M 5M 6M 1M 2M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 252M 236M 224M 215M 202M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO APVO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-11 2024-11-07 2024-08-08 2024-05-08 2023-09-30 2023-08-10 2023-05-11 2022-11-10 2022-08-11
acceptedDate 2025-11-06 16:18:03 2025-08-11 08:12:36 2025-02-14 08:52:59 2024-11-07 08:30:22 2024-08-08 08:30:27 2024-05-08 08:30:44 2024-03-05 08:30:32 2023-09-29 20:00:00 2023-08-10 08:30:35 2023-05-11 08:31:26 2023-03-30 08:01:58 2022-11-10 08:30:56 2022-08-11 08:31:34 2022-03-24 08:30:47 2021-03-31 08:00:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -8M -6M -24M -5M -6M -7M -17M -6M -8M 3M 8M -8M 28M -28M -18M
depreciationAndAmortization 49 000 49 000 352 000 84 000 91 000 106 000 567 000 123 000 150 000 178 000 901 000 222 000 276 000 1M 1M
deferredIncomeTax 0 0 0 0 0 0 0 -778 000 349 000 0 0 0 0 4000 0
stockBasedCompensation 77 000 -163 000 1M 149 000 273 000 719 000 2M 455 000 465 000 915 000 2M 359 000 485 000 2M 1M
changeInWorkingCapital 735 000 -775 000 -1M 1M -634 000 -642 000 3M -485 000 3M 690 000 2M 195 000 4M -3M -2M
accountsReceivables 0 0 0 0 0 0 3M 0 0 0 1M 0 0 -1M -2M
inventory 0 0 0 0 0 0 0 0 0 0 -1M 0 0 1M 0
accountsPayables 724 000 -501 000 -1M 2M -879 000 -926 000 518 000 -76 000 1M -909 000 -394 000 862 000 -1M -2M 0
otherWorkingCapital 11 000 -274 000 -59 000 -529 000 245 000 284 000 -107 000 -409 000 1M 909 000 3M -667 000 0 -740 000 665 000
otherNonCashItems 0 0 0 -2M 1M 2M 10000 778 000 -349 000 10000 -34M -28 000 -36M 7M -12M
netCashProvidedByOperatingActivities -7M -7M -24M -5M -6M -7M -12M -6M -5M 5M -21M -7M -3M -22M -29M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0 0 -29 000 -4000 -25 000 -713 000 -88 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 0 0 0 -4000 -25 000
debtRepayment 0 0 0 0 0 0 0 -3M -500 000 -500 000
commonStockIssued 18M 14M 5M 4M 0 1M 481 000 2M 0 436 000
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -11 000
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 -1000 -3000 3M 0 -8000 0 -3M
netCashUsedProvidedByFinancingActivities 18M 14M 5M 4M -3000 4M 481 000 -2M -500 000 -3M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 12M 7M -8M -313 000 -2M -7M -6M -2M -4M 3M -24M -7M -6M 4M 23M
cashAtEndOfPeriod 21M 9M 9M 8M 8M 10M 17M 19M 21M 25M 23M 23M 30M 46M 43M
cashAtBeginningOfPeriod 9M 2M 17M 8M 10M 17M 23M 21M 25M 23M 46M 30M 36M 43M 20M
operatingCashFlow -7M -7M -24M -5M -6M -7M -12M -6M -5M 5M -21M -7M -3M -22M -29M
capitalExpenditure 0 0 0 0 0 0 0 0 0 0 -29 000 -4000 -25 000 -713 000 -88 000
freeCashFlow -7M -7M -24M -5M -6M -7M -12M -6M -5M 5M -21M -7M -3M -22M -29M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-03-05 2023-03-30 2022-03-24 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 28M
netCashProvidedByInvestingActivities 0 0 -29 000 -713 000 28M
netDebtIssuance 0 -3M -12M -11M 3M
longTermNetDebtIssuance 0 -3M -12M -11M 3M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 10M 6M 7M 10M -11 000
netCommonStockIssuance 10M 6M 7M 10M -11 000
commonStockIssuance 10M 6M 7M 10M 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 6M 3M 3M 26M 21M
netCashProvidedByFinancingActivities 16M 6M -3M 26M 24M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

Press-releases

Show financial reports only

2026-09-24 ET
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
2026-09-03 ET
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
2026-08-14 ET
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
2026-08-13 ET
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
2026-08-12 ET
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
2026-07-27 ET
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
2026-06-30 12:05 ET
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
2026-06-09 ET
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category
2026-05-28 ET
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
2026-05-27 ET
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
2026-05-13 ET
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
2026-05-06 ET
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
2026-03-27 ET
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
2026-03-26 ET
Aptevo Provides State of the Business Report and 2025 Financial Results
2026-03-19 ET
Aptevo to Participate in March 2026 Conferences
2026-03-10 ET
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
2026-02-03 ET
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
2026-01-09 ET
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
2025-12-26 ET
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
2025-12-09 ET
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
2025-11-10 ET
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
2025-11-06 ET
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
2025-10-08 ET
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
2025-09-16 ET
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
2025-09-05 ET
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2025-09-04 ET
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
2025-08-13 ET
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
2025-08-11 ET
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
2025-08-08 ET
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2025-06-20 ET
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
2025-06-20 ET
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
2025-06-18 ET
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
2025-06-18 ET
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
2025-06-13 ET
Aptevo Participating in the BIO International Convention
2025-05-22 ET
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
2025-05-14 ET
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
2025-05-08 ET
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
2025-04-22 ET
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2025-04-21 ET
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2025-04-04 ET
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2025-04-03 ET
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2025-03-20 ET
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
2025-03-18 ET
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
2025-03-06 ET
Aptevo to Participate in March Conferences
2025-02-15 ET
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2025-02-14 ET
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
2025-01-15 ET
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
2024-12-12 ET
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
2024-12-12 ET
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
2024-12-04 ET
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
2024-11-29 ET
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
2024-11-26 ET
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
2024-11-22 ET
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
2024-11-20 ET
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
2024-11-11 ET
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
2024-11-07 ET
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
2024-10-29 ET
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
2024-09-18 ET
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
2024-09-16 ET
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
2024-09-16 ET
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
2024-09-13 ET
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
2024-08-13 12:05 ET
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
2024-08-08 12:05 ET
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
2024-07-01 20:20 ET
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
2024-06-28 13:20 ET
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
2024-06-03 12:05 ET
Aptevo Participating in the BIO International Convention
2024-05-14 12:05 ET
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
2024-05-08 12:05 ET
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
2024-04-15 20:05 ET
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
2024-04-15 20:05 ET
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
2024-04-11 12:00 ET
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
2024-04-11 12:00 ET
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
2024-04-10 13:00 ET
Aptevo Therapeutics Provides Pipeline Update
2024-03-18 10:00 ET
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
2024-03-07 13:55 ET
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
2024-03-05 13:05 ET
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
2024-03-04 14:00 ET
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
2023-11-14 13:05 ET
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
2023-11-01 11:45 ET
Aptevo to Present at Bio-Europe Conference
2023-08-10 12:05 ET
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
2023-08-04 22:40 ET
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
2023-08-04 ET
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
2023-08-02 02:15 ET
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
2023-08-01 ET
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
2023-07-18 12:05 ET
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
2023-05-11 12:05 ET
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
2023-03-30 11:45 ET
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
2023-03-30 11:30 ET
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
2023-03-30 ET
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
2023-02-13 13:05 ET
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
2023-01-09 13:05 ET
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
2022-12-12 12:35 ET
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
2022-11-10 13:05 ET
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
2022-11-09 13:05 ET
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
2022-11-03 13:06 ET
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
2022-09-19 12:45 ET
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
2022-08-11 12:05 ET
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
2022-06-09 12:05 ET
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
2022-05-12 12:05 ET
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
2022-04-12 12:05 ET
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
2022-03-29 12:05 ET
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
2022-03-24 12:05 ET
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
2022-02-09 13:05 ET
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
2022-02-09 ET
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
2022-01-21 13:05 ET
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
2021-12-15 13:36 ET
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
2021-12-15 13:05 ET
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
2021-11-23 13:05 ET
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
2021-11-15 13:05 ET
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
2021-11-12 13:05 ET
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
2021-11-11 21:45 ET
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
2021-11-11 13:30 ET
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
2021-10-27 12:05 ET
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
2021-10-26 12:05 ET
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
2021-09-28 12:05 ET
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
2021-08-17 12:05 ET
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
2021-08-12 12:05 ET
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
2021-07-16 12:05 ET
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
2021-06-30 12:05 ET
Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit
2021-06-29 12:05 ET
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
2021-05-27 13:00 ET
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
2021-05-26 13:00 ET
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
2021-05-11 13:00 ET
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
2021-04-09 13:00 ET
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
2021-03-31 12:00 ET
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
2021-02-10 00:30 ET
Aptevo Confirms Receipt of Nominations and Proposal Notice
2021-01-11 13:00 ET
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
2020-12-02 13:00 ET
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
2020-11-19 21:15 ET
Aptevo Confirms Receipt of Unsolicited Indication of Interest
2020-11-16 13:16 ET
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
2020-11-16 13:00 ET
Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
2020-11-10 21:40 ET
Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update
2020-11-09 14:00 ET
Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
2020-11-09 11:00 ET
Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
2020-11-09 04:15 ET
Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan
2020-11-03 14:00 ET
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
2020-09-01 13:00 ET
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
2020-08-14 13:00 ET
Aptevo Therapeutics Reports Second Quarter 2020 Financial Results
2020-08-06 13:00 ET
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust
2020-07-21 13:00 ET
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones
2020-06-29 13:00 ET
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale
2020-06-25 13:00 ET
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar
2020-06-10 13:00 ET
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
2020-05-13 13:00 ET
Aptevo Therapeutics Reports First Quarter 2020 Financial Results
2020-04-14 13:00 ET
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements
2020-03-25 13:00 ET
Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update
2020-03-16 13:00 ET
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial
2020-02-28 14:05 ET
Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million
2020-01-30 14:00 ET
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion
2019-12-06 14:00 ET
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
2019-11-08 14:00 ET
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
2019-11-07 14:00 ET
Aptevo Therapeutics Reports Third Quarter 2019 Financial Results
2019-10-03 20:02 ET
Aptevo Therapeutics Provides Corporate and Pipeline Update
2019-09-19 13:00 ET
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
2019-04-15 13:00 ET
Aptevo Therapeutics Reports IXINITY® and Pipeline Progress
2019-04-02 13:02 ET
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
2019-03-25 13:02 ET
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting

SEC forms

Show financial reports only

SEC form 8
2026-09-24 12:10 ET
Aptevo Therapeutics published news for 2026 q2
SEC form 8
2026-09-24 12:10 ET
Aptevo Therapeutics published news for 2026 q2
SEC form 8
2026-09-03 12:15 ET
Aptevo Therapeutics published news for 2026 q2
SEC form 8
2026-09-03 12:15 ET
Aptevo Therapeutics published news for 2026 q2
SEC form 10
2026-08-14 12:15 ET
Aptevo Therapeutics reported for 2026 q2
SEC form 8
2026-08-14 12:10 ET
Aptevo Therapeutics published news for 2026 q2
SEC form 8
2026-08-14 12:10 ET
Aptevo Therapeutics published news for 2026 q2
SEC form 8
2026-07-27 20:05 ET
Aptevo Therapeutics published news for 2026 q2
SEC form 8
2026-07-27 20:05 ET
Aptevo Therapeutics published news for 2026 q2
SEC form 8
2026-06-30 20:05 ET
Aptevo Therapeutics published news for 2026 q1
SEC form 8
2026-06-30 20:05 ET
Aptevo Therapeutics published news for 2026 q1
SEC form 10
2026-05-13 20:15 ET
Aptevo Therapeutics reported for 2026 q1
SEC form 8
2026-05-13 20:05 ET
Aptevo Therapeutics published news for 2026 q1
SEC form 8
2026-05-13 20:05 ET
Aptevo Therapeutics published news for 2026 q1
SEC form 8
2026-05-06 20:08 ET
Aptevo Therapeutics published news for 2026 q1
SEC form 8
2026-05-06 20:08 ET
Aptevo Therapeutics published news for 2026 q1
SEC form 10
2026-03-26 20:15 ET
Aptevo Therapeutics reported for 2025 q4
SEC form 8
2026-03-26 20:05 ET
Aptevo Therapeutics published news for 2025 q4
SEC form 8
2026-03-26 20:05 ET
Aptevo Therapeutics reported for 2025 q4
SEC form 8
2026-03-10 21:59 ET
Aptevo Therapeutics published news for 2025 q4
SEC form 8
2026-03-10 21:59 ET
Aptevo Therapeutics published news for 2025 q4
SEC form 8
2025-12-29 22:05 ET
Aptevo Therapeutics published news for 2025 q3
SEC form 8
2025-12-29 22:05 ET
Aptevo Therapeutics published news for 2025 q3
SEC form 10
2025-11-06 16:18 ET
Aptevo Therapeutics reported for 2025 q3
SEC form 8
2025-11-06 16:06 ET
Aptevo Therapeutics published news for 2025 q3
SEC form 8
2025-11-06 16:06 ET
Aptevo Therapeutics reported for 2025 q3
SEC form 8
2025-09-16 21:07 ET
Aptevo Therapeutics published news for 2025 q2
SEC form 8
2025-09-16 21:07 ET
Aptevo Therapeutics published news for 2025 q2
SEC form 8
2025-09-04 20:19 ET
Aptevo Therapeutics published news for 2025 q2
SEC form 8
2025-09-04 20:19 ET
Aptevo Therapeutics published news for 2025 q2
SEC form 10
2025-08-11 12:12 ET
Aptevo Therapeutics reported for 2025 q2
SEC form 8
2025-08-11 12:11 ET
Aptevo Therapeutics published news for 2025 q2
SEC form 8
2025-08-11 12:11 ET
Aptevo Therapeutics reported for 2025 q2
SEC form 8
2025-06-23 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-23 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 21:21 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 21:21 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-20 20:05 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-17 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-06-17 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-05-23 21:10 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-05-23 21:10 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 10
2025-05-15 20:10 ET
Aptevo Therapeutics reported for 2025 q1
SEC form 10
2025-05-15 00:00 ET
Aptevo Therapeutics reported for 2025 q1
SEC form 8
2025-05-15 00:00 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-05-15 00:00 ET
Aptevo Therapeutics reported for 2025 q1
SEC form 8
2025-04-29 21:06 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-29 21:06 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-22 20:14 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-22 20:14 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-22 20:14 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-22 20:14 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-22 20:14 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-22 20:14 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-04 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-04 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-04 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-04 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-04 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-04 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-04 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-04-04 20:15 ET
Aptevo Therapeutics published news for 2025 q1
SEC form 8
2025-03-20 12:44 ET
Aptevo Therapeutics published news for 2024 q4
SEC form 8
2025-03-20 12:44 ET
Aptevo Therapeutics published news for 2024 q4
SEC form 8
2025-03-20 12:44 ET
Aptevo Therapeutics published news for 2024 q4
SEC form 10
2025-02-14 08:52 ET
Aptevo Therapeutics reported for 2024 q4
SEC form 8
2025-02-14 08:50 ET
Aptevo Therapeutics published news for 2024 q4
SEC form 8
2025-02-14 08:50 ET
Aptevo Therapeutics reported for 2024 q4
SEC form 10
2025-02-14 00:00 ET
Aptevo Therapeutics reported for 2024 q4
SEC form 8
2025-02-11 13:37 ET
Aptevo Therapeutics published news for 2024 q4
SEC form 8
2025-02-11 13:37 ET
Aptevo Therapeutics published news for 2024 q4
SEC form 10
2024-11-07 08:30 ET
Aptevo Therapeutics reported for 2024 q3
SEC form 8
2024-11-07 08:15 ET
Aptevo Therapeutics published news for 2024 q3
SEC form 8
2024-11-07 08:15 ET
Aptevo Therapeutics reported for 2024 q3
SEC form 10
2024-08-08 00:00 ET
Aptevo Therapeutics reported for 2024 q2
SEC form 8
2024-08-08 00:00 ET
Aptevo Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 00:00 ET
Aptevo Therapeutics reported for 2024 q2
SEC form 10
2024-05-08 08:30 ET
Aptevo Therapeutics reported for 2024 q1
SEC form 8
2024-05-08 08:15 ET
Aptevo Therapeutics published news for 2024 q1
SEC form 8
2024-05-08 08:15 ET
Aptevo Therapeutics reported for 2024 q1
SEC form 10
2024-05-08 00:00 ET
Aptevo Therapeutics reported for 2024 q1
SEC form 10
2024-03-05 08:30 ET
Aptevo Therapeutics reported for 2023 q4
SEC form 10
2024-03-05 00:00 ET
Aptevo Therapeutics reported for 2023 q4
SEC form 8
2024-03-05 00:00 ET
Aptevo Therapeutics published news for 2023 q4
SEC form 8
2024-03-05 00:00 ET
Aptevo Therapeutics reported for 2023 q4
SEC form 10
2023-11-14 08:30 ET
Aptevo Therapeutics reported for 2023 q3
SEC form 8
2023-11-14 08:15 ET
Aptevo Therapeutics reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Aptevo Therapeutics reported for 2023 q3
SEC form 10
2023-08-10 08:30 ET
Aptevo Therapeutics reported for 2023 q2
SEC form 6
2023-08-10 08:16 ET
Aptevo Therapeutics reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Aptevo Therapeutics reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Aptevo Therapeutics reported for 2023 q2
SEC form 6
2023-08-04 18:51 ET
Aptevo Therapeutics published news for 2023 q2
SEC form 6
2023-07-18 08:16 ET
Aptevo Therapeutics published news for 2023 q2
SEC form 10
2023-05-11 08:31 ET
Aptevo Therapeutics reported for 2023 q1
SEC form 6
2023-05-11 08:15 ET
Aptevo Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Aptevo Therapeutics reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Aptevo Therapeutics reported for 2023 q1
SEC form 6
2023-04-18 08:30 ET
Aptevo Therapeutics published news for 2023 q1
SEC form 10
2023-03-30 08:01 ET
Aptevo Therapeutics reported for 2022 q4
SEC form 6
2023-03-30 07:50 ET
Aptevo Therapeutics reported for 2022 q4
SEC form 6
2023-03-30 07:40 ET
Aptevo Therapeutics published news for 2022 q4
SEC form 10
2023-03-30 00:00 ET
Aptevo Therapeutics reported for 2022 q4
SEC form 8
2023-03-30 00:00 ET
Aptevo Therapeutics reported for 2022 q4
SEC form 10
2022-11-10 00:00 ET
Aptevo Therapeutics reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Aptevo Therapeutics reported for 2022 q3
SEC form 10
2022-08-11 00:00 ET
Aptevo Therapeutics reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Aptevo Therapeutics reported for 2022 q2
SEC form 10
2022-05-12 00:00 ET
Aptevo Therapeutics reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Aptevo Therapeutics reported for 2022 q1
SEC form 10
2022-03-24 00:00 ET
Aptevo Therapeutics published news for 2021 q4
SEC form 8
2022-03-24 00:00 ET
Aptevo Therapeutics published news for 2021 q4
SEC form 10
2021-11-12 00:00 ET
Aptevo Therapeutics published news for 2021 q3
SEC form 8
2021-11-12 00:00 ET
Aptevo Therapeutics published news for 2021 q3
SEC form 10
2021-08-12 00:00 ET
Aptevo Therapeutics published news for 2021 q2
SEC form 8
2021-08-12 00:00 ET
Aptevo Therapeutics published news for 2021 q2
SEC form 10
2021-05-11 00:00 ET
Aptevo Therapeutics published news for 2021 q1